Theodore Stewart Gourdin

Title
InstitutionMedical University of South Carolina
DepartmentHematology/Oncology
AddressP.O. Box MSC 635
103
Basic Science Building - 173 Ashley Ave.
Phone843-792-4271
vCardDownload vCard

    Collapse Overview 
    Collapse keywords
    Cancer/Genitourinary, Women-s Health, Cancer, Drug Studies, Men-s Health

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gourdin T. Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal. Curr Opin Oncol. 2021 May 01; 33(3):252-256. PMID: 33818543.
      Citations:    
    2. Apolo AB, Ellerton JA, Infante JR, Agrawal M, Gordon MS, Aljumaily R, Gourdin T, Dirix L, Lee KW, Taylor MH, Schöffski P, Wang D, Ravaud A, Manitz J, Pennock G, Ruisi M, Gulley JL, Patel MR. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer. 2020 10; 8(2). PMID: 33037118.
      Citations:    
    3. Gourdin T. Recent progress in treating advanced prostate cancer. Curr Opin Oncol. 2020 05; 32(3):210-215. PMID: 32209821.
      Citations:    
    4. McElwee JH, Gourdin TS, Mikoll J, Weeda E, Sion AM. Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials. J Oncol Pharm Pract. 2020 Jun; 26(4):861-865. PMID: 31566113.
      Citations:    
    5. Gourdin T. Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future. Curr Opin Oncol. 2019 05; 31(3):188-193. PMID: 30925537.
      Citations:    
    6. Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer. 2019 05 01; 125(9):1459-1469. PMID: 30620391.
      Citations:    
    7. Shafqat H, Gourdin T, Sion A. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy. Semin Oncol. 2018 06; 45(3):156-163. PMID: 30348532.
      Citations:    
    8. Gourdin T, Sonpavde G. Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer. Asian J Androl. 2018 May-Jun; 20(3):230-237. PMID: 29578115.
      Citations:    
    9. Gourdin T. Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions. Curr Opin Oncol. 2018 05; 30(3):159-164. PMID: 29553949.
      Citations:    
    10. Gourdin TS, Zou Y, Ning Y, Emadi A, Duong VH, Tidwell ML, Chen C, Rassool FV, Baer MR. High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication. Cancer Genet. 2014 Oct-Dec; 207(10-12):467-73. PMID: 25441683.
      Citations:    
    11. Bhatnagar B, Duong VH, Gourdin TS, Tidwell ML, Chen C, Ning Y, Emadi A, Sausville EA, Baer MR. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Leuk Lymphoma. 2014 Jul; 55(7):1533-7. PMID: 24144313.
      Citations:    
    Gourdin's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (59)
    Explore
    _
    Co-Authors (2)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _